Viewing Study NCT04037566

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:01 PM
Ignite Modification Date: 2026-05-25 @ 4:15 AM
Study NCT ID: NCT04037566
Status: UNKNOWN
Last Update Posted: 2019-07-30
First Post: 2019-07-11
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.
Sponsor: Xijing Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Leukemia Lymphocytic Acute (ALL) in Relapse View
None Leukemia Lymphocytic Acute (All) Refractory View
None Lymphoma, B-Cell View
None CD19 Positive View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Leukemia Lymphocytic Acute View
None Lymphoma, B-Cell View